Related Experiment Video
Updated: Mar 7, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis
Giandomenico Roviello1,2,3, Karol Polom4, Franco Roviello4
1a Department of Oncology , Medical Oncology Unit, San Donato Hospital , Arezzo , Italy.
Abstract:
Angiogenesis is a key process in cancer development. We performed a meta-analysis to assess the efficacy and safety of the novel VEGFR-2 inhibitors in patients with metastatic gastric and gastroesophageal junction cancer. A literature-based meta-analysis of randomized controlled trials (RCTs) was undertaken. The primary outcome was the overall survival. The pooled analysis from RCTs on anti-VEGFR-2 inhibitors revealed a significant increase in overall survival (hazard ratio for death: 0.69, 95% confidence interval: 0.55-0.87; p = .002). This study confirms the efficacy of novel anti-VEGFR-2 inhibitors. The future studies of these agents will evaluate alone and in combination with chemotherapy the early line of treatment along with the identification of proper predictive biomarker.
Insights
Novel anti-angiogenic drugs targeting VEGFR-2 significantly improve overall survival in patients with advanced gastric cancer. Future research will explore their use in earlier treatment lines and identify predictive biomarkers.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a key mediator of angiogenesis and a target for cancer therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of novel VEGFR-2 inhibitors in metastatic gastric and gastroesophageal junction cancer.
- To assess the impact of these inhibitors on overall survival.
Main Methods:
- A literature-based meta-analysis of randomized controlled trials (RCTs) was conducted.
- The primary outcome measure was overall survival.
Main Results:
- The pooled analysis of RCTs demonstrated a significant improvement in overall survival for patients treated with anti-VEGFR-2 inhibitors.
- The hazard ratio for death was 0.69 (95% confidence interval: 0.55-0.87; p = .002), indicating a substantial survival benefit.
Conclusions:
- Novel anti-VEGFR-2 inhibitors are effective in improving overall survival for patients with metastatic gastric and gastroesophageal junction cancer.
- Future studies should investigate these agents in earlier treatment settings, both as monotherapy and in combination with chemotherapy, and identify predictive biomarkers for patient selection.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...